FDA faces outcry with Avastin breast-cancer choice


The latest debate over Roche's Avastin--whether the FDA should yank its approval for breast cancer use--shows how pulling a drug off the market is a lot more complicated than keeping it off the market to begin with.


[ Terug naar het hoofdmenu ]